Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study is a research paper published in Genetics in Medicine (2022). On theSindex it has a DataRank of 0.637. It has been cited 69 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.637
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIGMS NIH HHS
Grant: U19 GM061388
NIGMS NIH HHS
Grant: R01 GM125633
NIGMS NIH HHS
Grant: R01 GM028157
NIA NIH HHS
Grant: R33 AG058738
NIA NIH HHS
Grant: R01 AG034676
NHGRI NIH HHS
Grant: U01 HG005137
NHGRI NIH HHS
Grant: U01 HG006379
FWCI
10.58
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords